Table 3.
Comparison between the training cohort and the validation cohort of the Candiolo nomogram
| Clinical characteristics | Training cohort | Validation cohort |
|---|---|---|
| Sample size | 2,493 | 561 |
| Median Follow-up, mo | 50 | 50 |
| Mean age, yy | 71.7 | 71.9 |
| mean PSA, ng/ml | 15.0 | 12.93 |
| T staging, % | ||
| cT1 | 30.5% | 63% |
| cT2 | 57.5% | 33% |
| cT3-4 | 12% | 4% |
| bGS, % | ||
| ≤ 6 | 48% | 39% |
| 3 + 4 | 22% | 31% |
| 4 + 3 | 11.5% | 12% |
| 8 | 12% | 10% |
| 9–10 | 6.5% | 8% |
| Biopsy cores sampled, mean no | 10.3 | 11.0 |
| %PC, mean % | 44.3% | 41.3% |
| D’Amico risk class, % | ||
| Low | 21.5% | 21% |
| Intermediate | 32% | 40% |
| High | 46.5% | 39% |
| Candiolo risk class, % | ||
| Very-low | 21% | 24% |
| Low | 31% | 37% |
| Intermediate | 28% | 24% |
| High | 13% | 10% |
| Very-high | 7% | 5% |
| RT dose, ED2Gy | ||
| Mean (SD) | 75.5 (3.0) | 77.7 (2.4) |
| Median (min–max) | 76.0 (67.1–81.1) | 78.0 (72–82) |
| Exclusive RT, % | 38% | 24% |
| RT + ADT, % | 62% | 76% |